-Sanofi won approval for the use of a drug combination with its Sarclisa infusion to treat certain types of newly diagnosed multiple myeloma, where it has previously been used only after standard treatments have failed, the U.S. Food and Drug Administration said on Friday.
The French drugmaker, a market leader in anti-inflammatory drugs, has underscored its commitment to oncology drug development even after a once-promising breast cancer drug candidate flopped in 2022.
The FDA’s clearance came after a study showed a certain treatment regimen with Sarclisa lowered the risk of disease progression or death by 40% when compared to a treatment course without Sarclisa.
The drug was given FDA priority review status in May.
(Reporting by Ludwig Burger, Bhanvi Satija and Puyaan Singh in Bengaluru; Editing by Krishna Chandra Eluri)
